Welcome to our dedicated page for Swedish Orphan Biovitrum AB news (Ticker: SWOBY), a resource for investors and traders seeking the latest updates and insights on Swedish Orphan Biovitrum AB stock.
Swedish Orphan Biovitrum AB (Sobi), represented in U.S. markets by the ADR ticker SWOBY, is a global biopharma company that describes its mission as unlocking the potential of breakthrough innovations for people living with rare diseases. News related to SWOBY often reflects both its specialised role in rare disease biopharmaceuticals and its activities as a listed company on Nasdaq Stockholm under the symbol SOBI.
Investors and observers following SWOBY-related news can expect updates on corporate governance decisions, share capital measures and other company communications. For example, Sobi has reported on resolutions from its Annual General Meeting that authorise directed issues and repurchases of redeemable and convertible class C shares. These actions are described as being for the purpose of securing the company’s commitments under long-term incentive programmes.
News may also cover Board of Directors’ decisions to exercise repurchase authorisations, including details on the price relative to the quotient value of the share and the intended conversion of repurchased class C shares into common shares. Such announcements provide insight into how Sobi manages its equity structure and incentive arrangements.
Because Sobi identifies itself as a global biopharma company focused on rare diseases, company communications can also highlight its positioning within the healthcare sector and its global workforce across Europe, North America, the Middle East, Asia and Australia. For users tracking SWOBY, this news page serves as a central place to review official announcements, capital structure updates and other corporate information connected to Swedish Orphan Biovitrum AB.
Swedish Orphan Biovitrum (BIOVF) announced that its Board of Directors has authorized the repurchase of all issued class C shares following the Annual General Meeting resolution from May 8, 2025. The repurchase is specifically aimed at fulfilling commitments under the company's long-term incentive programmes.
The repurchase will be conducted at 100% of the quotient value (approximately SEK 0.55 per share) and will occur between July 16 and November 7, 2025. Following the repurchase and conversion of C shares to common shares, Sobi's total holdings of own common shares will increase from 11,377,680 to 12,790,468. The company reported revenue of SEK 26 billion in 2024 and employs approximately 1,900 people globally.
FAQ
What is the current stock price of Swedish Orphan Biovitrum AB (SWOBY)?
What is the market cap of Swedish Orphan Biovitrum AB (SWOBY)?
